| Budget Amount *help |
¥114,790,000 (Direct Cost: ¥88,300,000、Indirect Cost: ¥26,490,000)
Fiscal Year 2014: ¥20,670,000 (Direct Cost: ¥15,900,000、Indirect Cost: ¥4,770,000)
Fiscal Year 2013: ¥21,580,000 (Direct Cost: ¥16,600,000、Indirect Cost: ¥4,980,000)
Fiscal Year 2012: ¥22,620,000 (Direct Cost: ¥17,400,000、Indirect Cost: ¥5,220,000)
Fiscal Year 2011: ¥22,360,000 (Direct Cost: ¥17,200,000、Indirect Cost: ¥5,160,000)
Fiscal Year 2010: ¥27,560,000 (Direct Cost: ¥21,200,000、Indirect Cost: ¥6,360,000)
|
|---|
| Outline of Final Research Achievements |
Vasohibin-1 (VASH1) is an angiogenesis inhibitor expressed in endothelial cells, and the defect of its expression in ECs results in the enhancement of hematogenous and lymphatic cancer metastasis. There are 2 VASH1 proteins, a full length VASH1A and a splicing variant VASH1B. VASH1A causes angiogenesis inhibition and vascular maturation, whereas VASH1B causes endothelial cell death and vascular regression. Vasohibin-2 (VASH2) is an angiogenesis stimulator expressed in cancer cells, and the inhibition of its expression is useful for the anti-cancer treatment. VASH1 and VASH2 are highly conserved and resemble proteins. We analogized their active sites, developed neutralizing antibodies and identified a VASH receptor candidate.
|
